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Background:Bu is a drugused in conditioningprior toAlloSCTwith
a narrow therapeutic window. High Bu exposure can lead to veno-oc-
clusive disease, while lowBu exposure can result in graft failure. Every
6 hr IV Bu has been shown to be safe and effective at a dose of 4.0mg/
kg/day #4 years; 3.2 mg/kg/day .4 years. Age-based dosing adjust-
ments are suggested due to increased Bu metabolism in the very
young. However, data comparing the pharmacokinetic (PK) parame-
ters in IV q12 hr Bu regimens between these age groups is lacking.
Objective:We compared the PK parameters of a cohort of pediatric
AlloSCT recipients receiving IV Bu q12 hr 2 mg/kg/dose #4 years
(1.6 mg/kg/dose .4 years) stratified by age group.
Method:Blood was collected at 1, 2, 3, 5, 6, 7 and 8 hrs after the start
of first Bu infusion for concentration analysis. Bu PK parameters of
area under the curve (AUC), volume of distribution (Vd) and elimi-
nation constant (kel) were estimated by a single compartment first or-
der eliminationmodel. The secondary PK parameter of Bu clearance
(CL) was calculated using the formula CLBu5 Vd * kel. Both Vd and
CL were normalized (CLn) as a ratio to patient weight. The half-life
(t1/2) was calculated as 0.693/kel. The steady state concentration
(Css) was computed by dividing AUC by the dosing interval.
Results:The cohort of 49 IV Bu q12 hr recipients was age stratified
into pediatric recipients#4 years (n5 18) vs..4 years (\19 years [n
5 31]). In#4 years vs..4 years recipients normalized Vd was com-
parable (0.686 0.10 vs. 0.706 0.04 L/kg, p5 0.594). However, sig-
nificant differences were seen in PK parameters of elimination: t1/2
(115 6 21 vs. 146 6 16 min, p 5 0.008) and CLn (4.4 6 1.05 vs.
3.56 0.4 ml/min/kg, p5 0.038). (Table 1) Despite these differences
in t1/2 and CLn between age groups Css analyses (7006 115 vs. 679
6 77 ng/ml, p 5 0.702) showed no statistically significant differ-
ences. Targeted Bu Css was achieved in 61% of recipients#4 years,
and 55% of those .4 years. (p 5 0.669)
Conclusions: The significant difference in Cln and t1/2 emphasizes
the underlying Bu metabolism differences between age groups.
One known cause is the increased activity of glutathione-S-transfer-
ase in young children. The age-based dosing adjustment built into
the study demonstrates merit through comparable Bu Css in both
age groups. In summary, q12 hr IV Bu recipients #4 vs. .4 years
have different Bu PK, but achieve comparable Bu exposure with an
aged-based dosing adjustment.
Table 1. IV Bu q12 hr Pharmacokinetics Stratified by Age
# 4 years > 4 yearsAge Group pn 5 18 n 5 31Mean 95% CI Mean 95%CIAge (years) 2.0 1.4-2.6 10.5 8.6-12.4 <0.001
Weight (kg) 12.1 10.3-14.0 33.2 26.7-39.7 <0.001
Dose (mg/kg) 2.0 2.0-2.0 1.6 1.6-1.6 <0.001
Volume of
Distribution (L)0.68 0.58-0.78 0.70 0.66-0.74 0.594Half-life (min) 115 94-136 146 130-162 0.008
Clearance
(ml/min/kg)4.4 3.3-5.4 3.5 3.1-3.9 0.038AUC (mmol*min/L) 2047 1709-2385 1984 1757-2211 0.702
AUC/Day
(mmol*min/L)4094 3418-4771 3968 3515-4422 0.702Css (ng/ml) 700 585-816 679 601-756 0.702268
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Aim:To describe the outcome of haemopoietic stem cell transplants
(HCT) performed for paediatric patients with haematological malig-
nancies in Australia and New Zealand (ANZ).
Method: The Australasian Bone Marrow Transplant Recipient
Registry (ABMTRR) collects essential transplant and outcome
data for all HCT performed in ANZ. Eligibility criteria for this
retrospective registry analysis were patients up to the age of 18
years with a diagnosis of a haematologic malignancy who received
HCT at one of the 7 paediatric HCT centres in ANZ between
1998-2007. The Kaplan-Meier method was used to calculate the
probability of disease free survival (DFS) and overall survival
(OS). Cumulative incidence curves, with death from other causes
being treated as a competing event, were used to calculate the
probabilities of transplant related mortality (TRM) and relapse.
Cox multivariate regression analysis was used to investigate the
impact of recipient (age, disease status) and transplant (donor
type, stem cell source, conditioning) factors on relapse, TRM,
DFS and OS.
Results: 723 patients received 788 HCT (682 allogeneic, 106 au-
tologous). There were 58 2nd and 7 3rd HCT. Diagnoses for 1st
HCT included ALL (n 5 336), AML (n 5 249), NHL (n 5 47),
JMML (n 5 36), CML (n 5 19), MDS (n 5 22) and other leukae-
mias (n 5 14). Donor sources for 1st allogeneic HCT included
matched related (n 5 261), mismatched related (n 5 18), matched
unrelated (n 5 200) and mismatched unrelated(n 5 141 (84%
UCB)). Stem cell sources for 1st allogeneic HCT were BM (n 5
369), PBSC (n 5 69), UCB (n 5 167), dual UCB (n 5 13) and
BM/UCB (n 5 2). Myeloablative conditioning was used in 608
of 620 first allogeneic HCT. TRM at 1 year was 7.3% for matched
sibling (MSD), 23.2% for matched unrelated donors and 1.9% for
autologous transplants. Disease specific 5 year DFS and OS are
presented in Table 1. 5 year OS after 2nd or 3rd HCT was
60%. UCB as stem cell source (HR 0.61 (0.43-0.89) p 5 0.009)
and good risk disease (HR 0.56 (0.39-0.78) p 5 0.001) were asso-
ciated with a lower risk of relapse. Age\8 (HR 0.71 (0.55-0.91) p
5 0.008), MSD (HR 0.57 (0.43-0.75) p\0.001) and good risk
disease (HR 0.59 (0.43-0.79) p 5 0.001) were associated with
improved OS.
Table 1. Disease specific 5yr DFS and OS
Allogeneic HCT Autologous HCT5 yr DFS 5 yr OS 5 yr DFS 5 yr OSALL 50% 57%
AML 60% 62% 53% 65%
MDS 58% 62%
CML 41% 54%
JMML 56% 58%
NHL 48% 69%Conclusions: Outcomes of HCT for paediatric patients with hae-
matological malignancies in ANZ are very similar to published
CIBMTR data. The findings of an association between reduced
risk of relapse and use of UCB and the good results following 2nd
and 3rd HCT warrant further investigation.
